MedTrace Logo

Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke

NCT02448641 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2020-10-08

Study results available
· View outcomes & findings →

Summary

Controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke

Conditions

  • Chronic Ischemic Stroke

Interventions

BIOLOGICAL

SB623 Implant (2.5M)

2.5 million SB623 cells

BIOLOGICAL

SB623 Implant (5.0M)

5 million SB623 cells

PROCEDURE

Sham surgery

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    collaborator INDUSTRY

  • SanBio, Inc.

    lead INDUSTRY

Principal Investigators

  • Gary Steinberg, MD, PhD · Stanford Hospital and Clinics, School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-08
Primary Completion
2018-12-05
Completion
2018-12-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02448641 on ClinicalTrials.gov